Martha Bilbatua, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1548757404
Payments from drug & device makers
Across 367 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Dexcom, Inc.$881
- Corcept Therapeutics$501
- Amgen$495
- Insulet Corporation$494
- Lilly USA, LLC$384
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,142 |
| Dexcom, Inc. | 40 | $881 |
| Corcept Therapeutics | 35 | $501 |
| Amgen(2 entities) | 30 | $495 |
| Insulet Corporation | 50 | $494 |
| Lilly USA, LLC | 23 | $384 |
| Abbott | 14 | $338 |
| Radius Health, Inc. | 15 | $324 |
| Mannkind Corporation | 9 | $264 |
| Boehringer Ingelheim | 12 | $263 |
| BETA Bionics, Inc. | 8 | $205 |
| Tandem Diabetes Care, Inc. | 6 | $187 |
| Sanofi-aventis U.S. LLC | 8 | $163 |
| Ascendis Pharma Endocrinology Inc | 4 | $103 |
| Neurocrine Biosciences, Inc. | 4 | $99 |
| Sequel Med Tech, LLC | 5 | $94 |
| Chiesi USA, Inc. | 4 | $93 |
| Medtronic | 4 | $83 |
| Recordati_rare_diseases_inc. | 4 | $75 |
| Cequr Corporation | 3 | $53 |
| Eisai Inc. | 2 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| AbbVie | 3 | $45 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Boston Scientific | 1 | $37 |
| Currax Pharmaceuticals LLC | 2 | $35 |
| IBSA Pharma Inc. | 2 | $29 |
| Averitas Pharma Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Enterra Medical, Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$217
- Omnipod$122
- AFREZZA$113
How this compares
$6,724 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $162,346 |
| MounjaroTirzepatide | 74 | $100,567 |
| JardianceEmpagliflozin | 37 | $49,011 |
| TrulicityDulaglutide | 23 | $34,566 |
| FarxigaDapagliflozin Propanediol | 23 | $26,604 |
| RybelsusSemaglutide | 14 | $19,743 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,824 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $11,458 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $10,728 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $10,422 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 33 | $10,230 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $9,429 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $8,798 |
| Novolog FlexpenInsulin Aspart | 21 | $7,422 |
| SynthroidLevothyroxine Sodium | 60 | $6,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,142 | $182,089126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $384 | $135,13397 claims |
| Boehringer IngelheimJardiance | $263 | $49,01137 claims |
| AbbVieSynthroid | $45 | $6,16560 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,682193 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.